英製薬大手グラクソ・スミスクライン(GSK)が4月27日発表した2016年1~3月期(第1四半期)決算の純利益は2億8,200万ポンド(約3億6,300万ユーロ)となり、前年同期から97%減少した。前年同期にノバルティスへの腫瘍治療薬事業売却で大きな特別利益を計上した反動が出た。
本業はワクチン、大衆薬部門の販売増加に支えられて好調で、売上高は11%増の62億3,000万ポンドに拡大。営業利益は19%増加した。
Cookie | 期間 | 説明 |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |